Antengene Submits NDAs for XPOVIO® (Selinexor) in Multiple APAC Markets for rrMM and rrDLBCL

SHANGHAI and HONG KONG, Dec. 3, 2020 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in class therapeutics in hematology and oncology, announced it has submitted new drug...

Read more: Antengene Submits NDAs for XPOVIO® (Selinexor) in Multiple APAC Markets for rrMM and rrDLBCL

More Articles …

  1. Cloud, Cybersecurity, and Modernization Will Power Digital Business Models and Increased IT Spending, say Global 2000 Executives: Infosys - HFS Research
  2. PowerBuy Transforms Group Buying With Cash on Delivery, Launching Corporate Website
  3. Vinamilk's determination to expand its brand presence in Asia-Pacific region to achieve annual targets
  4. Applications for First IMA AsiaPac Student Case Competition Now Open
  5. Certis Launches Next-Generation Security Solution - Smart Networked Security
  6. meldCX unveils SAMi® - digitizing clean-up in public spaces with AI and computer vision
  7. Central IVF Limited's Egg Donation Service Recognized as One of The Most Reputable in Australia
  8. Rolls-Royce and Infosys Announce Strategic Partnership for Aerospace Engineering in India
  9. Poplin Data Promotes Chloe Sasson to CEO Appoints Board Of Advisors
  10. PixCell Medical to Enhance NSW Health Pathology's Point-of-Care Testing Service